| Outcome Measures: |
Primary: Fasting Serum Glucose, The fasting glucose levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12, Week 12|2 Hours After Oral Glucose Tolerance Test in Week 12, 2-h serum glucose levels were evaluated at week 12 after a oral glucose tolerance test with enzymatic/colorimetric techniques and the entered values reflect the insulin sensitivity at week 12, Week 12|Glycosylated Hemoglobin (A1C), Glycosylated hemoglobin was evaluated at week 12 by high pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at week 12, Week 12 | Secondary: Total Insulin Secretion, Total insulin secretion was calculated at week 12 with insulinogenic index and the entered values reflect the total insulin secretion at week 12. The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus. Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion, Week 12|Insulin Sensitivity, Insulin sensitivity was calculated at week 12 with Matsuda index and the entered values reflect the insulin sensitivity at week 12. Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index \[10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)\]. The entered values reflect the insulin sensitivity, Week 12|First Phase of Insulin Secretion, The first phase of insulin secretion was calculated at week 12 with Stumvoll index and the entered values reflect the frst phase of insulin secretion at week 12. Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis. First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion, Week 12|AUC Glucose, Area under the curve (AUC) of glucose was calculated with the polygonal formula. The area under the curve (AUC) of glucose, (0.5 \* glucose (G) 0´ + (G 30´+G 60´ + G 90´) + 0.5 \* G 120´) \* 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperglycemia., Week 12|AUC Insulin, Area under the curve (AUC) of insulin was calculated with the polygonal formula. The area under the curve (AUC) of insulin, (0.5 \* Insulin (I) 0´ + (I 30´+I 60´ + I 90´) + 0.5 \* I 120´) \* 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperinsulinemia., Week 12|Glucose 30 Min After Oral Glucose Tolerance Test at 12 Week, The glucose levels 30' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 30' at week 12, Week 12|Glucose 60 Min After Oral Glucose Tolerance Test at 12 Week, The glucose levels 60' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 60' at week 12, Week 12|Glucose 90 Min After Oral Glucose Tolerance Test at 12 Week, The glucose levels 90' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 90' at week 12., Week 12|Waist Circumference, Waist circumference was evaluated at week 12 with a flexible tape, Week 12|Body Weight, The body weight was measured at week 12 with a bioimpedance balance and the entered values reflect the body weight at week 12, Week 12|Body Mass Index, Body Mas Index was calculated at week 12 with the Quetelet index formula and the entered values reflect the body mass index at week 12, Week 12|Percentage of Fat Mass, Percentage of fat mass was evaluated through bioimpedance., Week 12|Total Cholesterol, Total cholesterol levels were evaluated at week 12 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 12, Week 12|Triglycerides, Triglycerides levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 12, Week 12|High Density Lipoprotein Cholesterol (c-HDL), c-HDL levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 12, Week 12|Low Density Lipoproteins Cholesterol (c-LDL), c-LDL levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at week 12, Week 12|Very Low Density Lipoprotein (c-VLDL), Very low density lipoprotein (c-VLDL) was analyzed with the cholesterol oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer., Week 12|Creatinine, Creatinine levels were evaluated at week 12 with enzymatic/colorimetric techniques, Week 12|Uric Acid, Uric acid levels were evaluated at week 12 with enzymatic/colorimetric techniques, Week 12|Systolic Blood Pressure, The systolic blood pressure was evaluated at week 12 with a digital sphygmomanometer and the entered values reflect the systolic blood pressure at week 12., Week 12|Diastolic Blood Pressure, The diastolic blood pressure was evaluated at week 12 with a digital sphygmomanometer and the entered values reflect the diastolic blood pressure at week 12., Week 12
|
